A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact - ScienceDirect
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma | Nature Communications
Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRASG12D mutated pancreatic cancer in vivo model | Cell Death Discovery
Biomedicines | Free Full-Text | Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety
Overall survival in folfirinox and gemcitabine/nab-paclitaxel groups... | Download Scientific Diagram
Cancers | Free Full-Text | Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer | British Journal of Cancer
Flowchart of phase II trial of nab-paclitaxel and gemcitabine | Download Scientific Diagram
Modified Nab-Paclitaxel/Gemcitabine in Pancreatic Cancer: Efficacious, Less Toxic, Less Costly - The ASCO Post
Coreprint PDF
GI Chemotherapy Education – GA/GemNab: Gemcitabine and Nab-paclitaxel (Abraxane®) - YouTube
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers | British Journal of Cancer
Main clinical trials with gemcitabine and nab-paclitaxel in other... | Download Table
nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. | Semantic Scholar
Cancers | Free Full-Text | Management of Pancreatic Cancer and Its Microenvironment: Potential Impact of Nano-Targeting
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine | NEJM
Antitumor effects of nab-paclitaxel with different regimens in... | Download Scientific Diagram
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study - The Lancet Gastroenterology & Hepatology
Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death
Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial - eClinicalMedicine
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial - Annals of Oncology
Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives - ScienceDirect
First Line Therapy for Metastatic Pancreatic Cancer
Metastatic Pancreatic Cancer: Current Treatment Options for Swiss Patients | Published in healthbook TIMES Oncology Hematology
Congestive Heart Failure Secondary to Gemcitabine Nab-paclitaxel in Patients with Pancreatic Cancer | Anticancer Research
ABRAXANE® for Metastatic Pancreatic Cancer | for HCPs
